Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Ovarian cancer: Current status and strategies for improving therapeutic outcomes.Cancer medicine · 2019
   Review
2. Silibinin restores the sensitivity of cisplatin and taxol in A2780-resistant cell and reduces drug-induced hepatotoxicity.Cancer management and research · 2019
   Article
3. Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.International journal of molecular sciences · 2017
   Review
4. HM015k, a Novel Silybin Derivative, Multi-Targets Metastatic Ovarian Cancer Cells and Is Safe in Zebrafish Toxicity Studies.Frontiers in pharmacology · 2017
   Article
5. Human papillomavirus oncoproteins differentially modulate epithelial-mesenchymal transition in 5-FU-resistant cervical cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
   Article
6. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.Journal of ovarian research · 2016
   Article
7. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.Oncotarget · 2016
   Article
8. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.Pathology oncology research : POR · 2015
   Article
9. Simulating cancer growth with multiscale agent-based modeling.Seminars in cancer biology · 2015
   Review
10. Endothelin-1/endothelin A receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis.Cellular signalling · 2014
    Article
11. Obesity increases tumor aggressiveness in a genetically engineered mouse model of serous ovarian cancer.Gynecologic oncology · 2014
    Article
12. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as